SFDA CEO Dr. Hisham Aljadhey Engages Pharmaceutical Executives To Enhance Investment Support

Dr. Hisham Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), recently engaged with leaders from local and international pharmaceutical firms at the SFDA headquarters in Riyadh. This meeting aimed to discuss vital issues and opportunities that could bolster the pharmaceutical sector's growth in Saudi Arabia. The gathering is part of SFDA's ongoing initiatives to strengthen partnerships with the private sector.

The discussions centred on regulatory strategies that create a sustainable investment environment, aligning with Saudi Vision 2030. Participants explored ways to enhance investment, innovation, and competitiveness within the Saudi pharmaceutical market. The focus was on reinforcing the Kingdom’s position as a leading hub for pharmaceuticals both regionally and globally.

During the meeting, participants examined challenges facing the private sector. They proposed practical solutions to ensure continued progress and sustainable growth in this crucial industry. This collaborative effort reflects SFDA’s commitment to transparency and active engagement with its partners.

The meeting also contributed to achieving objectives set by the Health Sector Transformation Program, a key initiative under Vision 2030. By fostering an enabling environment for collaboration between public and private sectors, SFDA aims to support its mission of protecting public health.

Ensuring access to safe, effective, and high-quality medicines remains a priority for SFDA. This commitment is evident in their efforts to maintain open communication channels with industry representatives, addressing current challenges while exploring future opportunities.

This engagement highlights SFDA's dedication to creating an attractive investment climate for pharmaceutical companies. By aligning regulatory strategies with national goals, they aim to attract more investments into the Kingdom’s pharmaceutical sector.

The meeting underscored SFDA's role in facilitating dialogue between stakeholders. It provided a platform for exchanging perspectives on strengthening further investment and innovation within the industry.

Overall, this initiative supports SFDA’s mission of ensuring public health safety while promoting growth within the pharmaceutical sector. Such efforts are crucial for positioning Saudi Arabia as a global leader in pharmaceuticals.

With inputs from SPA